At the White House on September 22, President Donald Trump told pregnant women to “tough it out” rather than take Tylenol. Surrounded by senior health officials, he presented new autism measures as a breakthrough. Yet the central uncertainty appeared in the government’s own announcement: researchers had not established that the painkiller causes autism.
What the White House Said, and What the FDA Could Prove
Speaking alongside Health and Human Services Secretary Robert F. Kennedy Jr., Trump repeatedly advised pregnant women to avoid acetaminophen, Tylenol’s active ingredient. He also urged families to delay hepatitis B vaccinations, separate the combined measles-mumps-rubella vaccine and spread childhood shots across more appointments. Extensive research has found no causal link between vaccines and autism.
The Food and Drug Administration responded by initiating a safety-label change for acetaminophen and alerting physicians to a possible association with autism and ADHD. But its September 22 notice also stated that “a causal relationship has not been established,” acknowledged studies finding no association and warned that untreated high fevers during pregnancy can pose risks.
The distinction between a possibility and a proven cause mattered. A precautionary warning, delivered without sufficient context, could discourage treatment for a documented danger.
The scientific record contained conflicting findings. An August review of 46 studies found evidence consistent with an association between prenatal acetaminophen exposure and neurodevelopmental conditions, without establishing causation. But a 2024 study published in JAMA, encompassing nearly 2.5 million Swedish children, found that a modest association disappeared when researchers compared siblings, better accounting for shared genetic and family factors. Neither the White House briefing nor its accompanying announcements supplied new evidence resolving that discrepancy.
The administration’s plans extended beyond Tylenol. Officials proposed expanding access to leucovorin, a form of folinic acid showing preliminary promise for certain communication difficulties among autistic children, particularly those with cerebral folate deficiency. HHS acknowledged that leucovorin was not a cure and that further research was needed. The National Institutes of Health also announced more than $50 million for 13 projects using data science to investigate autism’s biological, environmental and social factors. Kennedy framed the initiative as an answer to families seeking explanations and treatment options.
Professional opposition came quickly. The American College of Obstetricians and Gynecologists called the pregnancy advice irresponsible, reaffirming that acetaminophen, used appropriately, remains an important option for managing fever and pain. The American Academy of Pediatrics condemned misleading claims about vaccines and autism.
In a September 24 joint statement, autism and disability organizations challenged the evidence behind the administration’s claims and warned against portraying autism as a preventable consequence of parental decisions.
Families themselves were divided. In interviews with The Washington Post, some parents welcomed additional investigations into autism’s causes. Others said the announcement left them feeling blamed for decisions they had made under medical advice.
The Child Already Here
The controversy contained two competing time horizons. Federal officials were asking what might prevent an autism diagnosis years from now. Autistic young people were asking how to secure the support they need today.
The difference is more than philosophical. When the search for causes becomes the dominant public narrative, a diagnosis can begin to look like evidence of something that went wrong rather than information that helps someone live better.
A September 25 report in The Phoenix, Swarthmore College’s student newspaper, illustrated the consequences of that tension. Drawing on student interviews conducted earlier in the year, the report described Nathan ’28, who used only a first name for privacy and had considered pursuing an autism diagnosis to obtain academic accommodations.
After federal officials floated the idea of a national autism registry in April, Nathan reconsidered. Although the registry proposal was subsequently withdrawn, concerns about government access to personal information remained. Nathan told The Phoenix that a diagnosis no longer seemed worth pursuing.
Another student, Liam Muro ’28, described a contrasting experience. Muro, who is autistic, reported receiving effective academic accommodations and advocated making information about disability services a standard part of college orientation.
Together, their experiences expose a contradiction. A medical label can provide access to institutional support, yet the prospect of how that information might be collected or interpreted can discourage someone from seeking it.
Research into autism’s causes and possible therapies remains important, especially for families facing substantial daily support needs. HHS said its new research projects would include community engagement. But investigating how a condition develops is different from assigning responsibility for its existence. Without compelling evidence, the latter risks turning a child’s developmental differences into a retrospective judgment on a mother’s choices.
For a generation navigating increasingly data-driven healthcare and education, the stakes are immediate: Will an autism diagnosis help a student enter a classroom on fairer terms, or make that student hesitate before asking?
The government can spend years searching for what preceded a diagnosis. The student seeking accommodations needs an answer now.
Explore more exclusive insights at nextfin.ai.
